UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 9, 2025

MICROBOT MEDICAL INC.
(Exact name of registrant as specified in its charter)

Delaware	**000-19871**	**94-3078125**
(State or other jurisdiction of incorporation)	**(Commission File Number)**	**(IRS Employer Identification No.)**

175 Derby St., Bld. 27
Hingham, MA 02043
(Address of Principal Executive Offices) (Zip Code)

Registrant's telephone number, including area code: (781) 875-3605

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	**Trading Symbol(s)**	**Name of each exchange on which registered**
Common Stock, $0.01 par value	MBOT	NASDAQ Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging Growth Company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure.

On September 9, 2025, Microbot Medical Inc. (the "Company") released updated presentation materials. The presentation materials may be accessed via the 'Investors' section, under 'IR Resources' and then 'Additional Resources,' of the Company's website at www.microbotmedical.com. The Company is not undertaking to update these presentation materials.

As previously announced, the Company is attending the H.C. Wainwright Annual Investor Conference held in New York, New York, from September 8-10, 2025. Mr. Harel Gadot, the Company's President, CEO and Chairman, will present live on Tuesday, September 9, 2025 at 9:00 am ET, and a live webcast may be accessed via the 'Events' section of the Company's website at www.microbotmedical.com.

The presentation materials are also furnished as Exhibit 99.1 to this Current Report on Form 8-K, and are incorporated herein by reference. The information in this Item 7.01 and Exhibit 99.1 is being furnished and shall not be deemed to be "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. This report will not be deemed an admission as to the materiality of any information in this Item 7.01 or Exhibit 99.1.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit Number	Description
99.1	Presentation Materials
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

MICROBOT MEDICAL INC.

By: */s/ Harel Gadot*
Name: Harel Gadot
Title: Chief Executive Officer, President and Chairman

Date: September 9, 2025

Redefining Endovascular Robotics

microbot medical

Safe Harbor Statement

This document (together with any oral statements made in connection with this document) contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended, relating to future events or the future financial performance and operations of Microbot Medical, Inc. and its subsidiaries. Forward-looking statements, which involve assumptions and describe Microbot's intent, belief or current expectations about its business opportunities, prospects, performance and results, are generally identifiable by use of the words "may," "could," "should," "will," "would," "expect," "anticipate," "plan," "potential," "estimate," "believe," "intend," "project," "forecast," the negative of such words and other variations on such words or similar terminology. All statements other than statements of historical fact could be deemed forward-looking statements, including, but not limited to: the Company's need for and ability to obtain additional working capital to continue its transition to a commercially focused company; market conditions; risks inherent in the development and/or commercialization of the LIBERTY® Endovascular Robotic System; uncertainty in the results of regulatory pathways and regulatory approvals and the development of future versions or applications for the system; uncertainty resulting from political, social and geopolitical conditions, particularly any changes in personnel or processes or procedures at the FDA and the announcements of tariffs on imports into the U.S.; disruptions resulting from new and ongoing hostilities between Israel and the Palestinians, Iran and other neighboring countries; maintenance of intellectual property rights; our ability to leverage the experience of our management team; and any statements or assumptions underlying any of the items mentioned. These forward-looking statements are not guarantees of future performance and by their nature involve known and unknown risks and uncertainties that may cause actual opportunities, prospects, performance and results to vary from those presented in this document, and those variances may be material. In evaluating such statements, prospective investors should carefully consider the various risks and uncertainties identified in Microbot's public filings with the Securities and Exchange Commission (the "SEC"), such as market risk, liquidity risk, competitive risk, regulatory risk and other commonly recognized forms of risk relating to Microbot and its securities. In light of these risks, uncertainties and assumptions, the forward-looking events discussed in this document might not occur. Microbot is not obligated to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

This presentation shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of Microbot's securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.

Pivotal Company Development

- FDA granted 510(k) clearance for the LIBERTY® Endovascular Robotic System
- LIBERTY® is the first single-use, remotely operated robotic system for peripheral endovascular procedures
- The FDA clearance allows the Company to commence commercialization of the LIBERTY® in the U.S.
- Strategically target global markets that leverage FDA approved devices

Microbot Medical At-a-Glance

Large and Emergent Market

- Many endovascular procedures are life and limb saving interventions
- **>6 million** procedures in the USA (estimated 15 million worldwide)
- Performed by **>15,000** physicians (USA)
- **>$40B** annual spend (USA)

Significant Unmet Needs

- Difficulty navigating complex anatomy
- Healthcare providers at elevated risk of cancer and orthopedic problems
- Shortage of healthcare providers
- Limited access to quality care

Differentiated Robotic Solution

LIBERTY® is the world's first fully disposable robotic system designed to:

- Improve procedural efficiency
- Lower procedure costs
- Reduce risks of radiation exposure and physical strain (ergonomics)
- Enable access to quality care

First Mover Advantage

- **LIBERTY®** is the only single-use, remotely operated robotic system cleared by the FDA for peripheral endovascular procedures
- Clinical study shows 100% robotic navigation success rate
- IP portfolio of 13 granted patents and 56 pending patents globally

Attractive Reimbursement

- High procedure reimbursement for target procedures
- Capacity to incorporate new technologies
- Comparable pricing to other technologies used routinely in endovascular procedures

Unique Business Model

- Single use design reduces customer barriers to acquisition
- Eliminates upfront investment in expensive inventory build
- No expensive investment in services infrastructure
- Recurrence revenue from disposables and accessories

Go-to-Market Strategy

- Direct sales team in the USA focused on KOLs and high-volume facilities
- Collaborate with medical societies to increase **LIBERTY®** adoptions
- Utilize distribution partnerships and strategic partnerships to gain market access internationally

Experienced Team

- Led by a team with a proven track record of leading companies from inception to commercialization
- Supported by an experienced board of directors with high level, cross functional industry expertise
- Backed by global medical experts in the endovascular space

Source: AcuityMD procedure and physician database

Large and Emergent Market

- **>6 million annual endovascular procedures performed in the US (15 million worldwide)**
- **>$40B spent annually** in the US
- Performed by **15,000 physicians**
  - 9,000 interventional cardiologists
  - 3,000 interventional radiologists[1]
  - 3,000 vascular surgeons
- Performed at **8,000 facilities**
  - 3,500 hospitals
  - 4,500 ambulatory centers (ASCs/OBLs)
- Many **endovascular procedures are emergent**, life and limb saving interventions



Source: AcuityMD procedure and physician database
1. Includes interventional neuroradiologists which is a sub-specialty of IR

Initial Target Market: Peripheral Vascular



INITIAL TARGET PROCEDURES (USA):
2.3M

ANNUAL SPENDING (USA):
$15B

TARGET PHYSICIANS (USA):
6,000

AVG. ANNUAL # OF PROCEDURES PER PHYSICIAN (USA):
~400

FACILITIES PERFORMING PROCEDURES (USA):
2,200 Hospitals
1,000 Ambulatory Centers

Source: AcuityMD database

Significant Unmet Needs

Endovascular procedures are ripe for disruptive innovation that can improve procedure efficiency, HCP health & safety, while enabling access to quality care for both providers and patients

Procedure Efficiency

- Managing catheter and guidewire exchanges requires multiple clinical staff to handle the devices, thereby reducing procedure efficiency.
- Less experienced physicians face additional challenges in navigating complex vascular anatomy, negatively impacting procedure times and increasing radiation exposure.

Radiation Risks

- Endovascular procedures are time consuming and require clinicians to operate near the source of ionizing radiation.
- Despite wearing radiation protection equipment, providers who perform interventional radiology or cardiology procedures are 6 times more likely to develop cataracts and 3 times more likely to develop cancer during their careers.[1]

Ergonomic Issues

- Endovascular procedures are time consuming, and clinicians stand over the patient while wearing heavy lead protective equipment.
- Due to wearing heavy lead vests/protective equipment while performing the procedures, clinicians are 96% more likely to suffer from lower back pain and 21% more likely to miss work.[2,3]

Access to Quality Care

- Limited availability of experienced physicians and staffing shortage
- Lack of capital budget to purchase robotic technology
- Few community hospitals can perform advanced procedures, resulting in patients traveling long distances for life saving healthcare.

1. Andreassi MG, Piccaluga E, Guagliumi G, et al. Occupational health risks in cardiac catheterization laboratory workers. Circ Cardiovasc Interv. 2016,9:003273.
2. Andrew S, Abdelmonem M R, Kohli S, et al. (October 18, 2021) Evaluation of Back Pain and Lead Apron Use Among Staff at a District General Hospital. Cureus 13(10): e18859. DOI 10.7759/cureus.18859
3. Nicholas M. Orme et al. Occupational Health Hazards of Working in the Interventional Laboratory: A Multisite Case Control Study of Physicians and Allied Staff, Journal of the American College of Cardiology, Volume 65, Issue 8,

Clinical Outcomes from ACCESS-PVI Pivotal Study

Robotic manipulation of guidewires and catheters with LIBERTY® was successful in all cases, minimizing radiation exposure and maintaining a desirable safety profile[1]

Achieved
100%
Robotic Navigation Success in Every Case
(N = 20)

92%
Relative Reduction in Radiation Exposure

NO
Adverse Device Events Reported
(ADE = 0%)

Participating Physicians Reported LIBERTY Performed as Planned with
100%
Satisfaction

1. Cornelis F, Gandhi R, Rabkin D, Diaz-Cartelle J. Remote-controlled endovascular navigation with a miniature, single-use, robotic system. LBA15

Differentiated Robotic Solution

The LIBERTY® Endovascular Robotic System is disruptive technology designed to change the standard of care for endovascular procedures

- Single-use, fully-disposable without need for capital investment
- Empowers physicians to precisely steer guidewires and catheters using a handheld remote control away from the radiation source
- Small footprint that integrates into current procedure workflow
- No additional infrastructure required by the user
- Simple and intuitive set-up in under 5 minutes
- Short-learning curve to proficiency
- Compatible with off the shelf guidewires and catheters

1. Research report from wet-lab with 9 experienced interventional radiologists. Set-up times and learning curve will vary with user.

First Mover Advantage

LIBERTY® was designed to eliminate barriers and enable adoption of robotics in endovascular procedures

Barriers to Adoption	Other Robotic Systems	LIBERTY® Endovascular Robotic System
Cost of acquisition	✓ **Large** capital investment ✓ **Disposable** procedure kit ✓ **Annual service agreement**	✓ **Single-use (disposable) device** with no **initial acquisition cost**
Procedure set-up time	✓ **20 minutes extra** compared to conventional surgery[1]	✓ **5 minutes** to set-up the robot[3]
Learning curve	✓ Average **40-100 cases** depending on the procedure[2]	✓ **Less than 5 cases**[3]
Device compatibility	✓ Some require use of **proprietary instruments and devices**	✓ Compatible with **off-the-shelf instruments and devices**
Complex integration	✓ Requires a **dedicated room** and **integration with hospital IT systems**	✓ Can be used in **any angio-suite** and **does not need to connect with hospital IT**

1. Analysis of Procedure Time in Robot-Assisted Surgery: Comparative Study in Laparoscopic Cholecystectomy, Computer Aided Surgery, 8:1, 24-29, DOI: 10.3109/10929080309146099.
2. Systematic review of learning curves in robot-assisted surgery; BJS Open 2020; 4: 27–44.
3. Research report from wet-lab with nine experienced interventional radiologists. Set-up times and learning curve will vary with user.

First Mover Advantage

LIBERTY® is the only U.S. commercially available, single-use, robotic system for peripheral endovascular procedures

Several companies are developing robotic solutions due to the attractive market and untapped potential

Microbot is uniquely positioned for success with our unique design and first mover advantage in the US market

Company	Status	Target Procedures	USA Commercial Availability	No Capital Equipment	No Maintenance Required	No Infrastructure Required	Competitive Outlook
microbot medical	On the Market (U.S.)	Peripheral Vascular	✓	✓	✓	✓	CE Mark expected in late in 2026; will explore additional markets that leverage FDA clearance.
Robocath	On the market (Europe, China)	Cardiology	X	X	X	X	Focused on Europe & China. Large capital system with high cost and complex integration.
LN ROBOTICS	On the market (Korea only)	Cardiology	X	X	X	X	Focused on Korea. Large capital system with high cost and complex integration.
Corindus Vascular Robotics	Development stage	Neurovascular	X	X	X	X	Exited US cardiology market. Changed strategy from PCI to focus on Neurovascular.
sentante (Latvia)	Development stage	Peripheral Vascular	X	X	X	X	Completed one case in humans. Clinical, regulatory and operational complexity are unknown.
nanoflex robotics	Development stage	Neuro Vascular	X	X	X	X	Pre-clinical. Focused on telerobotics with magnetic steering. Cost and operational complexity are unknown.

Attractive Reimbursement

Targeted procedures have an attractive outpatient reimbursement with capacity to incorporate new technologies including LIBERTY®

Procedure	Description	CPT Code(s)	Avg. Reimbursement
Y90 for Liver Cancer	Part 1 – Mapping procedure Part 2 – Embolization procedure	Dx Angiogram (75726) Coil placement (37242) Embolization (37243) Y90 particles (C2616)	**$43,990.21**
Peripheral Embolization	For BPH, Uterine Fibroids, Hemorrhoids, Knee Osteoarthritis	Dx Angiogram (75726) Bland particle embolization (37242)	**$15,734.00**
Lower Limb Revascularization	Below the knee Chronic total occlusions	Dx Angiogram (75726) Angioplasty (37242)	**$15,856.00**
Vascular Hemorrhage	Place intravascular coils or glue to stop bleeding	Dx Angiogram (75726) Coil placement (37244)	**$15,734.00**

2024 Medicare/Medicaid average reimbursement
Actual reimbursement will vary and may be adjusted for cost of living
Private insurance typically billed at a higher rate

Unique Business Model

The fully disposable feature of LIBERTY® offers an attractive business model to position LIBERTY® for commercial success by reducing barriers for entry and increase operational efficiencies for all stakeholders

No Capital Investment

- No special Capital Expense (CAPEX) approval required by the customer. LIBERTY® can be purchased from the Operational Expense (OPEX) budget which will expedite the purchasing process.
- Cost effective evaluation process for customers at their facility can expedite purchasing decision.
- Eliminates the Company's investment in an expensive upfront and ongoing capital equipment inventory build-up, shipping, storage and management.

No Maintenance Expense

- Eliminates the cost for Microbot to hire, train, and manage a dedicated field service department.
- Eliminates the cost for Microbot to build dedicated warehouses and maintain inventory of replacement parts.
- Eliminates the cost for customers to pay for service and maintenance expenses.
- Eliminates risk of equipment down time.

No Custom Infrastructure

- Eliminates the process of fitting the technology to each specific customer (and sometime within a health system), to reduce expenses and expedite purchasing decision.
- Eliminates the investment in establishing, training, supporting and supplying technical team to support installations.
- LIBERTY® does not require investment in dedicated customer staff to provide on-going robotic program support.

Continuous Consumable Revenue

- Recurring revenue stream based on per device usage (or more) for a single procedure.
- LIBERTY® is a single SKU (Stock Keeping Unit) that can be utilized across many procedures, physicians and departments.

Commercialization Timeline

Successful execution of regulatory, commercial and launch readiness strategies

Go-to-Market Strategy

Company positioned to accelerate market adoption of the LIBERTY® system

- Dedicated direct sales team in the U.S., supplement with distribution channels as needed
- Increase manufacturing and build inventory levels to meet anticipated demand
- Limited Market Release (LMR) in Q4 2025 followed by a Full Market Release (FMR) expected in early 2026

Focused Growth Initiatives

In parallel with U.S. commercialization activities, Company remains focused on generating positive momentum with milestone achievements

- Expand U.S. and global sales footprint
- Strategically target markets that accept FDA cleared devices approval process to expedite future market entry
- Identify potential international distributor partnerships to gain access to local market knowledge and regulatory expertise
- Expand and protect the Company's intellectual property (IP) portfolio in key jurisdictions
- Leverage R&D pipeline to potentially address large addressable indications for neuro and cardiac
- Collaborate with like-minded companies and organizations to expand use of the LIBERTY® technology

Global Intellectual Property Portfolio

LIBERTY® is protected by a strong and growing intellectual property portfolio.

5	5	1	2
U.S.	Israel	China	Japan

Experienced Management Team

Harel Gadot
CEO, President & Chairman
LinkedIn

Simon Sharon
Chief Technology Officer
LinkedIn

Juan Diaz-Cartelle, MD
Chief Medical Officer
LinkedIn

Rachel Vaknin
Chief Financial Officer
LinkedIn

Earl Adamy
Vice President of Strategic
Marketing & Business Dev
LinkedIn

Eran Cohen
Vice President
of Global Integration
LinkedIn

Naama Moav
Vice President of HR
LinkedIn

Noa Ofer
Vice President of QA & RA
LinkedIn

Proven Commercial Leadership Team

Christina Bailey
Vice President of Sales
LinkedIn

Allison Rosefort
Vice President of Marketing
LinkedIn

Elaina Romano
Director of U.S. Operations
LinkedIn

Michael Lytle
Manager, Sales Operations & Analytics
LinkedIn

Lisa Dobbins
Director, Human Resources
LinkedIn

Summary

LIBERTY® is a differentiated solution in a large and emergent market, with clear unmet needs and attractive reimbursement

- Granted 510(k) clearance by U.S. FDA in September 2025 for the LIBERTY® Endovascular Robotic System, the first single-use, remotely operated robotic system for endovascular procedures.
- The endovascular market is large with more than 15 million endovascular procedures performed annually around the world, many of which are life saving and limb saving procedures.
- In the U.S., endovascular procedures historically have high reimbursement, with capacity for integrating new technologies like robotics that is expected to add value to all stakeholders.
- LIBERTY® improves access to robotic technology by eliminating the expensive capital investment and special infrastructure requirements.
- LIBERTY® enables physicians to remotely and safely perform procedures with precision away from harmful radiation exposure and reducing physical strain (ergonomics).
- LIBERTY® is designed to improve procedural efficiency by eliminating the need for assistance to hold wires and catheters, and to simplify the ability to access complex vascular anatomy.
- Commenced U.S. launch readiness activities in Q2 2025, with LMR in Q4 2025 and FMR expected in early 2026 followed by other regions that accept FDA cleared devices and a European launch during 2H 2026.

microbot medical

Contact Investor Relations

ir@microbotmedical.com
NASDAQ CM: MBOT

liberty
Endovascular Robotic System